Eosinophil-associated disorders (EADs), including eosinophilic gastrointestinal disorders, hypereosinophilic syndrome, and eosinophilic granulomatosis with polyangiitis are a heterogeneous group of conditions characterized by blood and/or tissue hypereosinophilia leading to eosinophil-mediated clinical manifestations. Recently, biologic therapies that target eosinophils have been developed and approved for some of the EADs, promising improved treatment options and outcomes for patients with these rare diseases.
However, responsiveness to eosinophil-targeted therapies is not universal in all EADs and predicting which patients will respond to which biologic therapy are some of the unanswered questions, which necessitate both basic and clinical studies into the mechanisms of EADs.
Suitable themes for manuscripts include, but are not limited to:
- Preclinical models of EADs or specific organ involvement (e.g. heart disease associated with hypereosinophilia)
- Mechanism of eosinophil-induced damage in EADs
- Interaction of eosinophils with immune and structural cells that are critical for pathophysiology of EADs
- Clinical outcomes and biomarkers of disease activity
- Predictors of response to eosinophil-targeted biologics
- Safety of eosinophil depletion
Keywords:
Eosinophil-associated diseases, Hypereosinophilic syndrome, Mechanism of disease, Biomarker ''biologic therapy, '' Eosinophilic gastrointestinal disorders
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
Eosinophil-associated disorders (EADs), including eosinophilic gastrointestinal disorders, hypereosinophilic syndrome, and eosinophilic granulomatosis with polyangiitis are a heterogeneous group of conditions characterized by blood and/or tissue hypereosinophilia leading to eosinophil-mediated clinical manifestations. Recently, biologic therapies that target eosinophils have been developed and approved for some of the EADs, promising improved treatment options and outcomes for patients with these rare diseases.
However, responsiveness to eosinophil-targeted therapies is not universal in all EADs and predicting which patients will respond to which biologic therapy are some of the unanswered questions, which necessitate both basic and clinical studies into the mechanisms of EADs.
Suitable themes for manuscripts include, but are not limited to:
- Preclinical models of EADs or specific organ involvement (e.g. heart disease associated with hypereosinophilia)
- Mechanism of eosinophil-induced damage in EADs
- Interaction of eosinophils with immune and structural cells that are critical for pathophysiology of EADs
- Clinical outcomes and biomarkers of disease activity
- Predictors of response to eosinophil-targeted biologics
- Safety of eosinophil depletion
Keywords:
Eosinophil-associated diseases, Hypereosinophilic syndrome, Mechanism of disease, Biomarker ''biologic therapy, '' Eosinophilic gastrointestinal disorders
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.